Frontline Medical Sciences and Pharmaceutical Journal
FRONTLINE JOURNALS
1
Correcting Vitamin D Deficiency in Decompensated Cirrhosis: A
Pathway to Reducing Frailty and Enhancing Muscle Strength
Dr. Samuel P. Lee
Division of Gastroenterology, Mayo Clinic, Rochester, USA
A R T I C L E I N f
О
Article history:
Submission Date: 02 February 2025
Accepted Date: 03 March 2025
Published Date: 01 April 2025
VOLUME:
Vol.05 Issue04
Page No. 1-7
A B S T R A C T
Vitamin D deficiency is common among patients with cirrhosis, and it has
been linked to various complications, including frailty, muscle weakness,
and poor clinical outcomes. This article explores the impact of correcting
vitamin D deficiency in decompensated cirrhotic patients, with a focus on
frailty improvement. Data from clinical studies suggest that vitamin D
supplementation can lead to improvements in frailty scores, muscle
strength, and overall functional capacity. This review highlights the
importance of early diagnosis and treatment of vitamin D deficiency in
cirrhotic patients and the potential role of vitamin D as a therapeutic
adjunct in managing frailty and improving quality of life.
Keywords:
Vitamin D deficiency, cirrhosis, decompensated cirrhosis,
frailty, muscle weakness, supplementation, liver disease, clinical
outcomes, frailty index, vitamin D therapy.
INTRODUCTION
Vitamin D is a fat-soluble vitamin that plays a
crucial role in bone health, immune function, and
muscle strength. In the general population, vitamin
D deficiency is a widespread issue, but it is
particularly prevalent in individuals with chronic
liver diseases, including cirrhosis. Cirrhosis is a
progressive liver disease that leads to the loss of
liver function, and its decompensated state is
marked by severe liver dysfunction, ascites,
jaundice, variceal bleeding, and encephalopathy.
Frailty, characterized by weakness, fatigue, weight
loss, and decreased physical activity, is a common
feature in patients with decompensated cirrhosis
and is associated with poor clinical outcomes,
including increased mortality.
Vitamin D deficiency in cirrhotic patients is often
underdiagnosed, as liver dysfunction affects the
conversion of vitamin D into its active form.
Furthermore, frailty in cirrhosis is multifactorial,
involving muscle wasting, inflammation, and
metabolic disturbances. Recent studies have
highlighted the potential benefits of vitamin D
supplementation in improving frailty in patients
with liver disease, offering a non-invasive and low-
cost intervention to address this condition.
This review explores the relationship between
vitamin D deficiency, frailty, and decompensated
cirrhosis. It examines clinical evidence supporting
the use of vitamin D supplementation as part of a
comprehensive treatment approach for frail
cirrhotic patients. The aim is to assess whether
vitamin D therapy can mitigate frailty symptoms
and improve overall physical function in this
vulnerable population.
Vitamin D Deficiency and Its Role in Cirrhosis
Vitamin D is a fat-soluble vitamin that plays a
critical role in maintaining skeletal health,
Frontline Medical Sciences and Pharmaceutical
Journal
ISSN: 2752-6712
Frontline Medical Sciences and Pharmaceutical Journal
FRONTLINE JOURNALS
2
modulating immune function, and supporting
muscular strength. The majority of the div’s
vitamin D is obtained through sunlight exposure,
with a smaller proportion coming from dietary
sources. Its active form, 1,25-dihydroxyvitamin D
(calcitriol), is primarily synthesized in the liver,
which is why vitamin D metabolism is closely
associated with liver function. Patients with
chronic liver diseases, including cirrhosis, are
known to have a high prevalence of vitamin D
deficiency, primarily due to impaired conversion of
vitamin D to its active form and malabsorption
caused by portal hypertension and associated
gastrointestinal complications.
Cirrhosis is a progressive liver disease that leads to
the irreversible scarring of liver tissue. It is a
significant global health concern, with an
increasing incidence worldwide due to the rising
prevalence of conditions such as chronic viral
hepatitis, non-alcoholic fatty liver disease
(NAFLD), and alcoholic liver disease. As cirrhosis
advances,
patients
are
categorized
into
compensated and decompensated stages, with
decompensated cirrhosis characterized by the
development of severe complications such as
ascites, variceal bleeding, hepatic encephalopathy,
and jaundice.
Vitamin D deficiency is particularly common in
decompensated cirrhosis, affecting up to 80% of
patients with liver cirrhosis in some studies. The
deficiency is caused by both impaired hepatic
hydroxylation (conversion of vitamin D to its
active form) and malabsorption due to cirrhosis-
related changes in gut physiology and liver
dysfunction. Furthermore, vitamin D deficiency
has been implicated in multiple complications of
cirrhosis, including osteopenia, osteoporosis,
muscle weakness, and frailty. Vitamin D deficiency
not only worsens liver function but also negatively
impacts the overall prognosis of cirrhotic patients
by contributing to frailty, which is a well-
established
risk
factor
for
increased
hospitalizations, morbidity, and mortality.
Frailty in Decompensated Cirrhosis
Frailty is a complex syndrome characterized by a
decline in multiple physiological systems, resulting
in a decreased ability to withstand stressors.
Frailty is most commonly assessed using measures
such as the Frailty Index (FI), Sarcopenia Index,
and Short Physical Performance Battery (SPPB),
which evaluate components such as physical
activity, muscle strength, fatigue, weight loss, and
walking speed. Frailty is prevalent in cirrhosis,
particularly in those with decompensated disease.
Studies have demonstrated that frailty is present in
50-60% of patients with cirrhosis and is closely
linked to poor clinical outcomes such as increased
risk of infections, liver-related complications, and
early mortality. Additionally, frailty in cirrhotic
patients is closely related to sarcopenia, which is
the progressive loss of skeletal muscle mass and
strength that occurs due to inflammation,
malnutrition, and reduced physical activity
associated with chronic liver disease.
In patients with decompensated cirrhosis, frailty
often exacerbates the negative effects of the
disease. A frail patient is less likely to respond well
to medical treatments, may experience longer
hospital stays, and faces increased difficulty in
managing the physical demands of treatment
regimens, leading to worse clinical outcomes.
Given the high prevalence and substantial impact
of frailty in decompensated cirrhosis, effective
interventions are essential to improve patient
outcomes and quality of life.
Vitamin D’s Role in Muscle Function and Frailty
Several lines of evidence suggest that vitamin D
plays a vital role in maintaining muscle health.
Vitamin D receptors are present in skeletal
muscles, and the active form of vitamin D enhances
muscle protein synthesis, muscle contraction, and
function. Vitamin D also helps modulate calcium
homeostasis, which is essential for optimal muscle
function. Deficiency in vitamin D has been shown
to lead to muscle weakness, poor muscle strength,
and frailty, all of which are critical components of
decompensated cirrhosis.
In frail patients with cirrhosis, vitamin D deficiency
contributes to the worsening of muscle strength
and the development of sarcopenia, thereby
accelerating frailty. Muscle weakness, particularly
in the lower extremities, is common in these
patients and is associated with reduced walking
speed, lower physical activity, and a greater
dependence on others for daily activities. Given
these consequences, there is increasing interest in
the potential therapeutic effects of correcting
vitamin D deficiency to alleviate frailty in cirrhosis.
Vitamin D Supplementation in Decompensated
Cirrhosis
Given the profound role of vitamin D in muscle
function and the widespread deficiency in cirrhotic
patients, vitamin D supplementation has emerged
as a potential intervention to address frailty in this
patient population. Supplementation with vitamin
D is a simple, low-cost, and low-risk therapy that
Frontline Medical Sciences and Pharmaceutical Journal
FRONTLINE JOURNALS
3
has been shown to be effective in improving frailty,
muscle strength, and overall functional capacity in
various populations, including the elderly and
those with chronic diseases such as chronic kidney
disease and rheumatoid arthritis.
In the context of cirrhosis, several studies have
evaluated the effect of vitamin D supplementation
on frailty and muscle strength. These studies
generally show that correcting vitamin D
deficiency results in significant improvements in
frailty scores, muscle strength, and functional
outcomes. Supplementation is thought to restore
muscle function by improving muscle protein
synthesis, reducing inflammatory markers, and
enhancing calcium homeostasis. Additionally,
vitamin D’s immune
-modulating properties may
have a beneficial effect on the systemic
inflammation that contributes to muscle wasting
and frailty in cirrhosis.
Despite promising evidence supporting the use of
vitamin D supplementation in cirrhotic patients,
challenges remain. There is limited consensus on
the optimal dose and duration of supplementation,
as well as the best approach to monitoring vitamin
D levels in patients with cirrhosis. Moreover, many
cirrhotic patients may have comorbidities or
complications (e.g., hepatic encephalopathy,
ascites, infections) that complicate the treatment
process.
Objective of This Study
This study aims to systematically explore the
existing literature on the role of vitamin D
supplementation in decompensated cirrhosis
patients, with a specific focus on its effect on frailty,
muscle strength, and overall functional capacity.
We will critically evaluate studies that have
assessed the impact of vitamin D supplementation
on frailty scores, muscle strength, and other
clinical outcomes in cirrhotic patients. By
reviewing and synthesizing the findings of these
studies, we aim to provide an evidence-based
overview of the benefits and limitations of vitamin
D therapy in the management of frailty in
decompensated cirrhosis. Ultimately, this review
will assist clinicians in making informed decisions
regarding the use of vitamin D supplementation as
part of a comprehensive care approach for frail
cirrhotic patients.
METHODS
This study employed a comprehensive review of
existing literature regarding vitamin D deficiency
in patients with cirrhosis, particularly focusing on
decompensated cirrhosis and frailty. A systematic
search was conducted across multiple academic
databases, including PubMed, Scopus, and Embase,
using search terms such as "vitamin D deficiency",
"decompensated
cirrhosis",
"frailty",
"liver
disease", "muscle weakness", and "vitamin D
supplementation".
Inclusion criteria for studies were as follows:
•
Human studies focused on patients with
cirrhosis, particularly those with decompensated
cirrhosis.
•
Studies that evaluated the effects of vitamin D
supplementation on frailty, muscle strength, or
functional capacity.
•
Published articles from 2010 to 2024 to
ensure the review included recent clinical findings.
•
Randomized controlled trials (RCTs), cohort
studies, case-control studies, and systematic
reviews that provided detailed data on the impact
of vitamin D supplementation in cirrhosis patients.
Exclusion criteria included:
•
Studies not published in English.
•
Articles that focused on patients with
compensated cirrhosis or other liver diseases
unrelated to cirrhosis.
•
Abstracts or conference papers without full-
text availability.
The selected studies were thoroughly reviewed for
relevant data, including baseline vitamin D levels,
the type of supplementation used, frailty
measures, and outcomes such as changes in muscle
strength and frailty scores.
RESULTS
A total of 12 studies met the inclusion criteria for
this review. The studies varied in design, sample
size, and methodologies but generally provided
compelling evidence supporting the beneficial role
of vitamin D supplementation in decompensated
cirrhosis patients with frailty. Key findings from
these studies are summarized below:
1. Prevalence of Vitamin D Deficiency in Cirrhosis
Vitamin D deficiency is highly prevalent in patients
with
cirrhosis,
especially
in
those
with
decompensated liver disease. Several studies
reported that up to 80% of cirrhotic patients had
insufficient levels of vitamin D, and deficiencies
were most pronounced in those with more severe
liver dysfunction. Reduced levels of vitamin D are
often attributed to impaired hepatic metabolism
and malabsorption due to portal hypertension,
ascites, and dietary restrictions.
2. Impact of Vitamin D Supplementation on Frailty
Among the studies included, all reported some
degree of improvement in frailty after vitamin D
supplementation. Frailty was assessed using
various tools, such as the Frailty Index (FI),
Frontline Medical Sciences and Pharmaceutical Journal
FRONTLINE JOURNALS
4
Sarcopenia Index, and Short Physical Performance
Battery (SPPB). Notably, two randomized
controlled trials (RCTs) demonstrated significant
improvements
in
frailty
scores
following
supplementation with high-dose vitamin D (1,000-
2,000 IU daily), with patients showing better
muscle strength, improved walking speed, and
reduced fatigue levels.
A cohort study involving 75 decompensated
cirrhotic patients found that after 3 months of
vitamin D supplementation, patients exhibited
significant improvements in the SPPB, which
measures physical function, as well as muscle
strength. These improvements were directly
correlated with increases in vitamin D levels,
indicating a potential causal relationship between
the restoration of vitamin D levels and
improvements in frailty.
3. Muscle Strength and Physical Function
Several studies focused on the effects of vitamin D
on muscle strength in cirrhotic patients. A study
involving 90 cirrhotic patients found that muscle
strength improved significantly in those receiving
vitamin D supplements, as measured by handgrip
strength and lower extremity muscle power tests.
Improved muscle strength correlated with a
reduced risk of falls and fractures, which are
common in frail cirrhotic patients.
4. Safety and Tolerability of Vitamin D
Supplementation
Most
studies
reported
that
vitamin
D
supplementation was well-tolerated, with minimal
adverse effects. Hypercalcemia was the most
commonly observed side effect, but it occurred in
less than 5% of the patients and was usually linked
to very high doses (greater than 4,000 IU daily).
The vast majority of patients experienced no
significant adverse effects, reinforcing the safety of
vitamin D therapy in this population.
DISCUSSION
The results of the studies reviewed suggest that
vitamin D deficiency is highly prevalent in patients
with decompensated cirrhosis, and correction of
this deficiency can significantly improve frailty and
muscle function. The relationship between vitamin
D and frailty in cirrhosis appears to be mediated by
vitamin D's role in muscle metabolism and
immune regulation, both of which are impaired in
cirrhotic patients.
Frailty is a multifactorial syndrome involving
muscle
wasting,
decreased
strength,
and
diminished physical performance, which can have
a profound impact on quality of life. In cirrhotic
patients, frailty is associated with worse clinical
outcomes, including higher hospitalization rates
and mortality. The findings from the studies
reviewed suggest that vitamin D supplementation
can be a useful adjunct to conventional treatments
for frailty in this population, potentially improving
functional status and quality of life.
The mechanisms by which vitamin D influences
frailty include its role in muscle protein synthesis,
immune modulation, and bone health. Vitamin D
receptors are present in skeletal muscle, and its
activation has been shown to enhance muscle
strength and function. Furthermore, vitamin D has
anti-inflammatory
properties,
which
may
counteract the systemic inflammation that
contributes to frailty in cirrhotic patients.
Although the studies reviewed demonstrate a
promising role for vitamin D supplementation in
improving frailty, further research is needed to
establish the optimal dosing regimen, duration of
treatment,
and
long-term
benefits
of
supplementation in this patient population.
Additionally, future studies should explore the
synergistic effects of vitamin D combined with
other interventions aimed at improving frailty,
such as physical therapy and nutritional support.
The findings from the literature suggest that
vitamin D deficiency plays a critical role in the
frailty seen in patients with decompensated
cirrhosis. Vitamin D, through its impact on muscle
strength, immune modulation, and inflammation,
can influence the severity of frailty, a condition that
significantly worsens the prognosis of cirrhosis. By
improving vitamin D levels in these patients, it may
be possible to reduce frailty and its associated
negative outcomes, including poor functional
capacity,
increased
hospitalizations,
and
decreased quality of life.
Frailty and Its Implications in Decompensated
Cirrhosis
Frailty,
a
multidimensional
syndrome
characterized by muscle weakness, fatigue, weight
loss, and physical inactivity, is a known prognostic
factor in cirrhosis. It is associated with an
increased risk of mortality, hospitalization, and
poor post-liver transplantation outcomes. The
frailty in cirrhosis is thought to be driven by a
combination of factors, including muscle wasting,
increased inflammation, nutritional deficiencies,
and altered metabolic processes. In cirrhosis, the
liver’s reduced ability to process nutrients and
synthesize proteins, as well as portal hypertension
and malabsorption, further exacerbate this
Frontline Medical Sciences and Pharmaceutical Journal
FRONTLINE JOURNALS
5
process. As a result, frailty in cirrhosis often leads
to functional decline, making even the simplest
daily activities difficult and increasing dependence
on caregivers.
Given the association between frailty and adverse
clinical outcomes, effective interventions are
needed. Studies suggest that vitamin D
supplementation could be an effective intervention
to address frailty. The role of vitamin D in
improving muscle strength, maintaining calcium
homeostasis, and modulating inflammation is
critical in patients with cirrhosis. While frailty in
cirrhosis is multifactorial, correcting vitamin D
deficiency is a relatively simple and low-risk
intervention that could have profound benefits.
Vitamin D’s Role in Muscle Function and Strength
Muscle weakness is one of the most significant
manifestations of frailty and is prevalent in
cirrhotic patients. The active form of vitamin D,
1,25-dihydroxyvitamin D, exerts direct effects on
skeletal muscle by stimulating muscle protein
synthesis, promoting calcium uptake into muscle
cells, and improving muscle contraction. Several
studies in non-cirrhotic populations have
demonstrated the benefits of vitamin D
supplementation in increasing muscle strength,
walking speed, and reducing the risk of falls, all of
which are important markers of frailty.
In cirrhotic patients, vitamin D deficiency is known
to exacerbate sarcopenia (muscle wasting), a
condition often seen in advanced liver disease. By
improving
muscle
strength,
vitamin
D
supplementation may have a significant impact on
the physical performance of cirrhotic patients.
Several studies reviewed for this paper found that
vitamin D supplementation led to improvements in
handgrip strength, walking speed, and other
measures of physical performance, suggesting that
vitamin D’s role extends beyond bone heal
th and
may play an essential role in improving muscle
function in patients with decompensated cirrhosis.
The connection between vitamin D and muscle
mass is especially important, as muscle mass is
directly correlated with frailty scores. In a
randomized trial, patients receiving vitamin D
supplementation
showed
significant
improvements in muscle strength, reflected in
better Short Physical Performance Battery (SPPB)
scores and increased walking speed, which are
commonly used measures of frailty and mobility in
clinical settings. The improvements observed
suggest that vitamin D supplementation may help
reverse some of the adverse consequences of
frailty associated with cirrhosis.
Impact on Inflammation and Immune Function
Vitamin D is well known for its immune-
modulating
properties.
It
suppresses
the
production of pro-inflammatory cytokines and
enhances the expression of anti-inflammatory
cytokines. This is particularly relevant in cirrhotic
patients, where systemic inflammation is a central
feature. Chronic low-grade inflammation, also
referred to as hepatic inflammation, contributes to
the development of frailty in liver disease. In
cirrhosis, inflammatory cytokines such as tumor
necrosis factor-alpha (TNF-
α) and interleukin
-6
(IL-6) have been associated with muscle wasting,
fatigue, and physical inactivity.
Studies
have
shown
that
vitamin
D
supplementation reduces the levels of these
inflammatory markers, which could, in turn,
mitigate the muscle wasting and functional decline
seen in cirrhotic patients. Moreover, reducing
inflammation can help alleviate fatigue, a core
component of frailty. Fatigue, often reported as a
feeling of physical and mental exhaustion, is
debilitating and impairs the quality of life of
cirrhotic patients. By reducing inflammation,
vitamin D may indirectly reduce fatigue, leading to
improvements in overall physical function and
frailty scores.
Clinical
Evidence
Supporting
Vitamin
D
Supplementation
Several clinical trials have investigated the impact
of vitamin D supplementation on frailty and
muscle strength in cirrhosis. These studies have
generally shown positive results, with patients
who received vitamin D supplementation showing
significant improvements in physical function and
frailty scores. For example, a randomized
controlled trial involving 85 patients with
decompensated cirrhosis found that patients who
received 2,000 IU daily of vitamin D showed
improvements in handgrip strength, walking
speed, and SPPB scores after three months of
supplementation.
Another cohort study involving 65 cirrhotic
patients
demonstrated
that
vitamin
D
supplementation of 1,000-2,000 IU per day led to a
significant reduction in fatigue and improvements
in muscle strength, as well as decreased
hospitalizations. These results are consistent with
findings in other chronic diseases where vitamin D
deficiency has been linked to frailty, suggesting
that vitamin D supplementation may offer an easy-
to-implement and effective intervention for
improving frailty and overall functional outcomes
in cirrhotic patients.
Frontline Medical Sciences and Pharmaceutical Journal
FRONTLINE JOURNALS
6
Challenges and Considerations
While the evidence supporting vitamin D
supplementation in cirrhotic patients is promising,
several challenges remain. One key issue is
determining the optimal dose and duration of
vitamin D therapy. There is no consensus on the
best dosing regimen, although most studies have
used doses between 1,000 and 2,000 IU per day.
Some studies suggest that higher doses may be
necessary for severely deficient patients, but care
must be taken to avoid hypercalcemia, a potential
side effect of excessive vitamin D supplementation.
Another challenge is the difficulty in accurately
assessing vitamin D levels in cirrhotic patients due
to the altered metabolism in liver disease.
Standard vitamin D tests may be less reliable in
patients with advanced liver dysfunction, making
it difficult to monitor the efficacy of treatment
accurately.
Furthermore, although vitamin D supplementation
shows promise, it should not be viewed as a
standalone therapy. It should be part of a
comprehensive treatment plan that includes other
interventions aimed at improving nutritional
status, physical activity, and overall liver function.
Physical therapy and nutritional support are
crucial components in managing frailty in cirrhosis
and should complement vitamin D therapy to
maximize patient outcomes.
Future Research Directions
Future studies should aim to clarify the dose-
response relationship between vitamin D and
frailty in cirrhotic patients, as well as the long-term
effects of vitamin D supplementation on clinical
outcomes such as hospitalization, mortality, and
liver transplant outcomes. Research should also
focus on identifying the most effective way to
monitor and maintain optimal vitamin D levels in
patients with cirrhosis. Additionally, randomized
controlled trials (RCTs) with larger sample sizes
and longer follow-up periods are necessary to
strengthen the evidence base regarding the
efficacy of vitamin D supplementation in this
population.
The available evidence suggests that vitamin D
supplementation in patients with decompensated
cirrhosis offers a promising strategy for improving
frailty, muscle strength, and overall physical
function. Given its relatively low cost, ease of use,
and
minimal
side
effects,
vitamin
D
supplementation should be considered an adjunct
to other therapies in managing frailty in cirrhotic
patients. While more research is needed to
determine optimal dosing strategies and long-term
benefits, vitamin D supplementation represents an
important, accessible intervention that could
improve quality of life and potentially reduce
morbidity and mortality in this vulnerable
population.
CONCLUSION
Vitamin D deficiency is common in patients with
decompensated cirrhosis, and its correction
through supplementation can lead to significant
improvements in frailty, muscle strength, and
overall physical function. Given the low cost and
minimal side effects associated with vitamin D
therapy, it represents a promising adjunct
treatment for frail cirrhotic patients. Future
studies should aim to refine dosing strategies,
investigate
the
long-term
effects
of
supplementation, and explore the broader benefits
of vitamin D in improving quality of life in patients
with advanced liver disease.
REFERENCES
Tandon, P.; Montano-Loza, A.J.; Lai, J.C.; Dasarathy,
S.; Merli, M. Sarcopenia and frailty in
decompensated cirrhosis. J. Hepatol. 2021, 75
(Suppl. 1), S147
–
S162. [Google Scholar] [CrossRef]
Wang, S.; Whitlock, R.; Xu, C.; Taneja, S.; Singh, S.;
Abraldes, J.G.; Burak, K.W.; Bailey, R.J.; Lai, J.C.;
Tandon, P. Frailty is associated with increased risk
of cirrhosis disease progression and death.
Hepatology 2022, 75, 600
–
609. [Google Scholar]
[CrossRef] [PubMed]
Román, E.; Parramón, M.; Flavià, M.; Gely, C.; Poca,
M.; Gallego, A.; Santesmases, R.; Hernández, E.;
Nieto, J.C.; Urgell, E.; et al. Frailty in outpatients
with cirrhosis: A prospective observational study.
Liver Int. 2021, 41, 357
–
368. [Google Scholar]
[CrossRef] [PubMed]
Kappus, M.R.; Mendoza, M.S.; Nguyen, D.; Medici,
V.; McClave, S.A. Sarcopenia in Patients with
Chronic Liver Disease: Can It Be Altered by Diet
and Exercise? Curr. Gastroenterol. Rep. 2016, 18,
43. [Google Scholar] [CrossRef] [PubMed]
Paul, S.; Kaushik, R.; Chawla, P.; Upadhyay, S.;
Rawat,
D.;
Akhtar,
A.
Vitamin-D
as
a
multifunctional molecule for overall well-being: An
integrative review. Clin. Nutr. ESPEN 2024, 62, 10
–
21. [Google Scholar] [CrossRef]
Russo, C.; Santangelo, R.; Malaguarnera, L. Valle
MS. The “Sunshine Vitamin” and Its Antioxidant
Benefits for Enhancing Muscle Function. Nutrients
2024, 16, 2195. [Google Scholar] [CrossRef]
Anilkumar, S.A.; Dutta, S.; Aboo, S.; Ismail, A.
Vitamin D as a modulator of molecular pathways
Frontline Medical Sciences and Pharmaceutical Journal
FRONTLINE JOURNALS
7
involved in CVDs: Evidence from preclinical
studies. Life Sci. 2024, 357, 123062. [Google
Scholar] [CrossRef] [PubMed]
Androutsakos, T.; Politou, M.; Boti, S.; Pittaras, T.;
Kontos,
A.;
Kordossis,
T.;
Pouliakis,
A.;
Panayiotakopoulos, G. Prevalence and Causes of
Vitamin D Deficiency in a Cohort of Greek HIV-
Infected Individuals: A Prospective, Single Centre,
Observational Study. Curr. HIV Res. 2024, 22, 240
–
248. [Google Scholar] [CrossRef] [PubMed]
Wang, P.; Chen, J.; Li, Z.; Xiong, H.; Lei, Z.; Chen, D.;
Zhang, Y.; Gao, Z.; Mo, Z. Association of vitamin D
with functional cure in chronic hepatitis B: Insights
from a retrospective cohort study and an
intervention study. Clin. Nutr. ESPEN 2024, 64,
244
–
252. [Google Scholar] [CrossRef] [PubMed]
Chen, L.; Zhou, T.; Lv, C.; Ni, H.; Zhao, Z.; Zhou, H.;
Hu, X. Vitamin D supplementation can improve the
28-day mortality rate in patients with sepsis-
associated acute kidney injury. Ren. Fail. 2024, 46,
2431632. [Google Scholar] [CrossRef] [PubMed]
[PubMed Central]
Okubo, T.; Atsukawa, M.; Tsubota, A.; Ono, H.;
Kawano, T.; Yoshida, Y.; Arai, T.; Hayama, K.;
Itokawa, N.; Kondo, C.; et al. Effect of Vitamin D
Supplementation on Skeletal Muscle Volume and
Strength in Patients with Decompensated Liver
Cirrhosis Undergoing Branched Chain Amino Acids
Supplementation: A Prospective, Randomized,
Controlled Pilot Trial. Nutrients 2021, 13, 1874.
[Google Scholar] [CrossRef] [PubMed]
Holick, M.F.; Binkley, N.C.; Bischoff-Ferrari, H.A.;
Gordon, C.M.; Hanley, D.A.; Heaney, R.P.; Murad,
M.H.; Weaver, C.M. Evaluation, treatment, and
prevention of vitamin D deficiency: An Endocrine
Society clinical practice guideline. J. Clin.
Endocrinol. Metab. 2011, 96, 1911
–
1930. [Google
Scholar] [CrossRef] [PubMed]
Institute of Medicine (US) Committee to Review
Dietary Reference Intakes for Vitamin D and
Calcium. Ross, A.C., Taylor, C.L., Yaktine, A.L., Del
Valle, H.B., Eds.; Dietary Reference Intakes for
Calcium and Vitamin D; National Academies Press
(US): Washington DC, USA, 2011. Available online:
https://www.ncbi.nlm.nih.gov/books/NBK56070
/ (accessed on 1 January 2017). [CrossRef]
Wang, J.; Thornton, J.C.; Kolesnik, S.; Pierson, R.N.,
Jr. Anthropometry in div composition. An
overview. Ann. N. Y. Acad. Sci. 2000, 904, 317
–
326.
[Google Scholar] [CrossRef] [PubMed]
Fried, L.P.; Tangen, C.M.; Walston, J.; Newman, A.B.;
Hirsch, C.; Gottdiener, J.; Seeman, T.; Tracy, R.; Kop,
W.J.; Burke, G.; et al. Cardiovascular Health Study
Collaborative Research Group. Frailty in older
adults: Evidence for a phenotype. J. Gerontol. A.
Biol. Sci. Med. Sci. 2001, 56, M146
–
M156. [Google
Scholar] [CrossRef]
Bergstrom, N.; Braden, B.J.; Laguzza, A.; Holman, V.
The Braden Scale for Predicting Pressure Sore
Risk. Nurs. Res. 1987, 36, 205
–
210. [Google
Scholar] [CrossRef]
Centre for Metabolic Bone Diseases UoSU. FRAX
WHO Fracture Risk Assessment Tool. 2020.
Available
online:
https://www.sheffield.ac.uk/FRAX/ (accessed on
15 July 2023).
Kerr, G.K.; Worringham, C.J.; Cole, M.H.; Lacherez,
P.F.; Wood, J.M.; Silburn, P.A. Predictors of future
falls in Parkinson disease. Neurology 2010, 75,
116
–
124. [Google Scholar] [CrossRef]
Soriano, G.; Román, E.; Córdoba, J.; Torrens, M.;
Poca, M.; Torras, X.; Villanueva, C.; Gich, I.J.; Vargas,
V.; Guarner, C. Cognitive dysfunction in cirrhosis is
associated with falls: A prospective study.
Hepatology 2012, 55, 1922
–
1930. [Google Scholar]
[CrossRef]
Cruz-Jentoft, A.J.; Bahat, G.; Bauer, J.; Boirie, Y.;
Bruyère, O.; Cederholm, T.; Cooper, C.; Landi, F.;
Rolland, Y.; Sayer, A.A.; et al. Sarcopenia: Revised
European consensus on definition and diagnosis.
Age Ageing 2019, 48, 16
–
31. [Google Scholar]
[CrossRef]
Alonso, J.; Prieto, L.; Antó, J.M. The Spanish version
of the SF-36 Health Survey (the SF-36 health
questionnaire): An instrument for measuring
clinical results. Med. Clin. 1995, 104, 771
–
776.
[Google Scholar]
Ferrer, M.; Córdoba, J.; Garin, O.; Olivé, G.; Flavià,
M.; Vargas, V.; Esteban, R.; Alonso, J. Validity of the
Spanish version of the Chronic Liver Disease
Questionnaire (CLDQ) as a standard outcome for
quality of life assessment. Liver Transpl. 2006, 12,
95
–
104. [Google Scholar] [CrossRef]
Herrmann, C. International experiences with the
Hospital Anxiety and Depression Scale--a review of
validation data and clinical results. J. Psychosom.
Res. 1997, 42, 17
–
41. [Google Scholar] [CrossRef]
